Metabolic Dysregulation in Fatty Liver Disease

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 946

Special Issue Editors


E-Mail Website
Guest Editor
School of Medicine, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, 70200 Kuopio, Finland
Interests: metabolomics; omics-integration; gut microbiota; metabolic diseases; molecular nutrition

E-Mail Website
Guest Editor
Advanced Institute of Medical Sciences, Dalian Medical University, Dalian 116044, China
Interests: prostanoid; G protein-coupled receptor; nuclear receptor; hypertension; non-alcoholic fatty liver disease; diabetes; acute renal injury; chronic kidney disease

Special Issue Information

Dear Colleagues,

Fatty liver disease (FLD) is a growing global health crisis, associated with high morbidity, mortality, and significant economic burden. It is characterized by the accumulation of fat in the liver cells, primarily due to metabolic dysfunction. Key risk factors for FLD include excessive alcohol consumption, obesity, diabetes, hepatitis C infection, hormonal imbalances, certain surgeries, medications, and genetic polymorphisms (such as PNPLA3 and TM6SF2). The disease is driven by insulin resistance, oxidative stress, and inflammation, leading to disrupted lipid and glucose metabolism. Despite its increasing prevalence, FLD has not received the attention that other related conditions, such as diabetes and obesity, have garnered.

Recent advancements in metabolomics have provided new insights into the complex metabolic pathways involved in FLD. These studies highlight the critical role of metabolites in interorgan communication and systemic metabolic regulation. This Special Issue focuses on the metabolic dysregulation underlying FLD and explores the disease’s connections to other metabolic disorders. By bringing together multidisciplinary research, the Issue aims to advance the molecular understanding of FLD, identify novel biomarkers, and uncover new therapeutic targets.

This collection offers valuable insights for researchers, clinicians, and public health experts interested in the far-reaching impacts of metabolic dysregulation in FLD, while also pointing towards promising strategies for prevention and treatment.

Dr. Ambrin Farizah Babu
Prof. Dr. Youfei Guan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolic dysregulation
  • metabolic homeostasis
  • insulin resistance
  • oxidative stress
  • lipid metabolism
  • glucose metabolism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

34 pages, 1818 KiB  
Review
From Childhood Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Hyperlipidemia Through Oxidative Stress During Childhood
by Siham Accacha, Julia Barillas-Cerritos, Ankita Srivastava, Frances Ross, Wendy Drewes, Shelly Gulkarov, Joshua De Leon and Allison B. Reiss
Metabolites 2025, 15(5), 287; https://doi.org/10.3390/metabo15050287 - 24 Apr 2025
Viewed by 697
Abstract
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is rapidly becoming the most prevalent form of chronic liver disease in both pediatric and adult populations. It encompasses a wide spectrum of liver abnormalities, ranging from simple [...] Read more.
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is rapidly becoming the most prevalent form of chronic liver disease in both pediatric and adult populations. It encompasses a wide spectrum of liver abnormalities, ranging from simple fat accumulation to severe conditions such as inflammation, fibrosis, cirrhosis, and liver cancer. Major risk factors for MASLD include obesity, insulin resistance, type 2 diabetes, and hypertriglyceridemia. Methods: This narrative review employed a comprehensive search of recent literature to identify the latest studies on the relationship between MAFLD and obesity, the health consequences and the latest treatment options to prevent long-term damage to the liver and other organs. Additionally, the article presents perspectives on diagnostic biomarkers. Results: Childhood obesity is linked to a multitude of comorbid conditions and remains a primary risk factor for adult obesity. This abnormal fat accumulation is known to have long-term detrimental effects into adulthood. Scientific evidence unequivocally demonstrates the role of obesity-related conditions, such as insulin resistance, dyslipidemia, and hyperglycemia, in the development and progression of MASLD. Oxidative stress, stemming from mitochondrial dysfunction, is a leading factor in MASLD. This review discusses the interconnections between oxidative stress, obesity, dyslipidemia, and MASLD. Conclusions: Atherogenic dyslipidemia, oxidative stress, inflammation, insulin resistance, endothelial dysfunction, and cytokines collectively contribute to the development of MASLD. Potential treatment targets for MASLD are focused on prevention and the use of drugs to address obesity and elevated blood lipid levels. Full article
(This article belongs to the Special Issue Metabolic Dysregulation in Fatty Liver Disease)
Show Figures

Figure 1

Back to TopTop